Literature DB >> 2870686

Central and peripheral effects of S 3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] in animal models.

P A van Zwieten, M J Thoolen, F A Jonkman, B Wilffert, A de Jonge, P B Timmermans.   

Abstract

The effects on blood pressure and heart rate of S 3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] were investigated in rats and cats. Upon i.v. injection in pithed rats, S 3341 produced pressor responses which were antagonized by prazosin as well as by yohimbine. In pentobarbitone-anesthetized rats S 3341 produced a short-lasting increase in mean arterial pressure, followed by a long-lasting reduction. During a 12-day, continuous subcutaneous infusion in conscious spontaneously hypertensive rats, S 3341 reduced blood pressure and heart rate. Upon cessation of treatment, an overshoot of heart rate and blood pressure lability occurred. The hypotensive effect was abolished by reserpinization of the rats. S 3341 was more potent in reducing mean arterial pressure upon infusion via the vertebral artery than after infusion via the femoral artery of chloralose-anesthetized cats. S 3341 did not prolong the hexobarbitone-induced loss of righting reflex in mice. S 3341 was more potent in displacing [3H]clonidine than [3H]prazosin from their specific binding sites in rat brain membranes. These data characterize S 3341 as a clonidine-like, centrally acting antihypertensive drug. The lack of sedative effect, as assessed by the prolongation of hexobarbitone-induced sleeping in mice, remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870686

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  8 in total

Review 1.  Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.

Authors:  P Bousquet; J Feldman
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

2.  Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects.

Authors:  A T Dinh Xuan; R Matran; J Regnard; P Vitou; C Advenier; A Lockhart
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

Review 3.  The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.

Authors:  P Ernsberger; J E Friedman; R J Koletsky
Journal:  J Hypertens Suppl       Date:  1997-01

4.  Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit.

Authors:  J Feldman; E Tibiriça; G Bricca; M Dontenwill; A Belcourt; P Bousquet
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

5.  Dose-effect relationship of rilmenidine after chronic administration.

Authors:  R Luccioni; M Lambert; P Ambrosi; M Scemama
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Influence of anaesthesia on the cardiovascular effects of rilmenidine and clonidine in spontaneously hypertensive rats.

Authors:  F Sannajust; C Cerutti; E Koenig-Bérard; J Sassard
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

7.  Electrophysiological effects of intravenous rilmenidine in man.

Authors:  J Tonet; C Guillet; G Jondeau; F Poulain; P Vivet; R Frank; Y Grosgogeat
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Sympathoinhibition by rilmenidine in conscious rabbits: involvement of alpha 2-adrenoceptors.

Authors:  B Szabo; R Urban; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.